Mitsubishi Tanabe Pharma Corporation

Yahoo Japan Corporation

Sanofi

Kazuki Nakayama

Kazutoshi Watanabe

Daiki Sakai

Toshiyuki Kohara

Kenji Fukunaga

Akira Tajima

Koji Tsukamoto

Fumiaki Uehara

Tatsuaki Suzuki

Yoshihiro Usui

Keiichi Aritomo

Kiyoshi Sasaki

Satoshi Yokoshima

Takahiro Ishikawa

Seira Nakamura

Narae Lee

Shin-ichi Kusaka

An information processing device according to the present application includes a generation unit and a providing unit. The generation unit uses a model that is trained to learn a relationship between a criterion for classifying users of a first company and a criterion for classifying users of a second company to generate a criterion (common key) for classifying the users of the second company into a first category, from the criterion for classifying the users of the first company into the first category. The providing unit provides a criterion generated by the generation unit.

Information processing device, information processing method, and non-transitory computer readable storage medium

A non-transitory computer-readable recording medium includes instructions that cause a computer to execute a process that includes receiving, from a server of a second provider that provides a service for supporting a delivery of a content performed by a first provider, encrypted information along with the content. The first provider encrypts information on the service to obtain the encrypted information. The process also includes attempting decoding the encrypted information, which is received in the receiving, by using a decoding key that is provided by the first provider and determining reliability of the service based on a decoded result in the decoding.

Computer-readable recording medium, terminal device, and terminal controlling method for determining service provider reliability

A distribution apparatus includes a receiving unit and a distributing unit. The receiving unit receives an acquisition request for a first content. The distributing unit distributes the first content displayed with a second content and control information that causes a region of the second content that does not overlap the first content to be displayed in a selectable state and causes a region of the second content overlapping the first content to be displayed so as to overlap the first content in a non-selectable state, when the acquisition request is received by the receiving unit.

Distribution apparatus, terminal apparatus and distribution method

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C&#x2014;F or the like; Rrepresents a C-Calkyl group;Y represents oxygen atom or N&#x2014;R; R, R, R, R, Rand Reach independently represents hydrogen atom, a C-Calkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

3-[1,4]oxazepane-4-pyrimidone derivatives

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom or C&#x2014;X; X represents hydrogen atom or fluorine atom; Ris hydrogen atom or a C-Calkyl group; L represents single bond or a C-Calkylene group which may be substituted; Y represents single bond, sulfur atom, oxygen atom, NH, or the like; Rrepresents hydrogen atom or a cyclic group which may be substituted, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Pyrimidone derivatives

A pyrimidone derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents hydrogen atom and Y represents hydroxyl group, or X represents fluorine atom and Y represents hydrogen atom; Rrepresents a Calkyl group; Rrepresents a morpholin-4-yl group which may be substituted, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Pyrimidone compounds

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein Rrepresents a hydrogen or the like; Rrepresents methyl group or the like; Rrepresents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; Rrepresents hydrogen or the like; Rrepresents hydrogen or the like; Rrepresents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH, oxygen atom, NH, or the like; any one or more of Rand R, Rand R, Rand R, X and R, X and R, X and R, and Rand Rmay combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Growing community of inventors

Tokyo, Japan

Kazuki Nakayama